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LETTERS TO THE EDITOR
Progestagens for granulosa cell tumours of the ovary
Sir - Further to the recent article by Malik and Slevin
'Medroxyprogesterone Acetate (MPA) in advanced granulosa
cell tumours of the ovary - a new therapeutic approach?' we
would like to describe two similar cases which also have
shown a response to progestagens.
Case I
A 68 year old multiparous woman presented with a granu-
losa cell tumour of the left ovary. At laparotomy the tumour
was found to be adherent to the rectum with omental meta-
stases and she proceeded to bilateral salpingo-oopherectomy
and partial omentectomy with no residual macroscopic
disease left after surgery. She was initially treated with mon-
thly Chlorambucil for 14 months without evidence of tumour
progression until treatment was stopped due to mylosuppres-
sion.
Two months after stopping chemotherapy she was found
to have a large right pelvic mass on CT scan and was
commenced on MPA 200 mg t.i.d. with complete remission
achieved on CT scan after 4 months of treatment. MPA was
continued.
Three and a half years later she relapsed with a further
large lower abdominal mass extending into the pelvis and
failed to respond to second line hormonal manipulation with
Tamoxifen. At laparotomy a large, mainly solid, but partly
cystic, tumour was found adherent to the right broad liga-
ment, posterior uterus and residual omentum. There was also
significant iliac lymphadenopathy. The tumour was debulked
and histology showed recurrent malignant sex cord stromal
tumour, entirely composed of thecal malignancy which had
replaced the previous granulosa cell component. One year
after surgery she remains well with no clinical evidence of
recurrence on no medical treatment.
Case 2
A 62 year old multiparous woman presented with abdominal
distension and back pain and was found to have a pelvic
mass. At laparotomy a large tumour was found to occupy
much of the abdominal cavity and involved small and large
bowel. She had a debulking procedure and histology showed
a granulosa cell tumour.
Of note in her past medical history 18 years previously, she
had had a total abdominal hysterectomy and bilateral
salpingo-oophorectomy for what she described as an ovarian
cyst. Unfortunately histology from this surgery is not
available, but in retrospect this may have been a granulosa
cell tumour.
Following her more recent surgery an ultrasound scan
revealed a residual left pelvic mass and she proceeded to
receive six courses of Cisplatinum in a dose of 50 mgm-2
combined with Chlorambucil 10 mg daily for 7 days. She had
achieved complete remission on ultrasound after six courses
of treatment and proceeded to receive eight courses of treat-
ment. Three years after completing chemotherapy she was
found clinically to have a mass at the vaginal vault and on
CT scan a 12 x 8 cm pelvic mass was found. She was com-
menced on Tamoxifen, but after 4 months of treatment was
shown to have progressed on CT scan with increased size of
the pelvic mass associated with ascites and obstruction of the
left kidney. She had an unsuccessful attempt at debulking
laparotomy and was commenced on Megestrol Acetate in a
dose of 160 mg daily. After 5 months of treatment she was
found to have had a marked response on CT scan particular-
ly on the left side of the tumour with resolution of her
ascites.
These cases again demonstrate that progestagens can induce
tumour regression in advanced cases of granulosa cell
tumours and support the view expressed by Malik and Slevin
that this drug could be considered as first line therapy for
patients who have relapsed and in whom surgery is inappro-
priate.
R. Isaacs
G. Forgeson
S. Allan
Radiotherapy and Medical Oncology Department,
Palmerston North Hospital,
Ruahine Street,
Palmerstone North,
New Zealand.
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